双歧杆菌
乳糖
乳糖不耐受
益生元
益生菌
长双歧杆菌
医学
短双歧杆菌
叙述性评论
食品科学
生理学
生物
乳酸菌
细菌
重症监护医学
发酵
遗传学
作者
Sindusha Mysore Saiprasad,Olivia Grace Moreno,Dennis A. Savaiano
出处
期刊:Nutrients
[MDPI AG]
日期:2023-08-12
卷期号:15 (16): 3559-3559
被引量:4
摘要
Supplementation with the probiotic Bifidobacterium and prebiotic galacto-oligosaccharides (GOS) could improve gut health and benefit lactose intolerant individuals. A narrative review was conducted to identify human clinical trials that evaluated lactose digestion and/or tolerance in response to consumption of Bifidobacterium, GOS, or both. A total of 152 studies on Bifidobacterium and GOS or both were published between 1983 and 2022. Out of the 152 studies, 20 were human clinical trials conducted in lactose intolerant subjects; 8 studies were conducted with Bifidobacterium supplementation and 3 studies involved GOS supplementation. Five studies reported favorable outcomes of Bifidobacterium supplementation in managing lactose intolerance (LI). Similarly, three studies reported favorable outcomes with GOS supplementation. The other three studies reported neutral outcomes. In conclusion, most studies reported a favorable effect of Bifidobacterium and GOS on managing the symptoms of LI. No study has examined the effects of combined supplementation with Bifidobacterium and GOS in lactose intolerant subjects. Future research could examine if co-supplementation with Bifidobacterium and GOS is a more effective strategy to reduce the dairy discomfort in LI individuals.
科研通智能强力驱动
Strongly Powered by AbleSci AI